H.C. Wainwright has reiterated its Buy rating for Silence Therapeutics (NASDAQ:SLN), maintaining a price target of $75.00 after engaging with the company’s management on January 13. This valuation suggests substantial appreciation potential compared to the stock's current trading price near $5.82, with analyst price targets spanning from $4 to $75, data from InvestingPro shows.
The research firm cited management’s strong optimism regarding the lead candidate divesiran, designed to treat polycythemia vera (PV). The Phase 2 SANRECO trial has achieved full enrollment of 48 patients, with topline data anticipated in the third quarter of 2026. H.C. Wainwright believes this program represents the most imminent catalyst for value creation, based on encouraging durability of effect and flexible dosing observed during Phase 1 assessments.
In addition, Silence Therapeutics’ lipoprotein(a) targeting drug zerlasiran is positioned for Phase 3 readiness. The potential upside for this program is linked to an expected cardiovascular outcomes study from Novartis in the first half of 2026, which could validate the therapeutic class.
Investors have also shown interest in other pipeline assets, including SLN365 aimed at severe hypercholesterolemia, SLN098 for obesity, and innovations in extra-hepatic delivery methods. These programs collectively illustrate the versatility and scalability of the company’s proprietary mRNA interference (mRNAi) GOLD platform. According to InvestingPro, Silence Therapeutics maintains robust gross margins of 91.32%, underscoring the commercial promise of its technology.
H.C. Wainwright underscores the company's evolution from focusing on a single lead asset to pursuing multiple developmental opportunities, a strategy supported by prudent capital deployment and an extended cash runway projected through 2028. Financial metrics as analyzed by InvestingPro indicate that Silence Therapeutics has more cash than debt, a strong current ratio of 7.69, though the company is experiencing rapid cash burn.
Looking ahead, Silence Therapeutics is scheduled to report its next earnings on March 18. Related updates include the completion of patient enrollment for the SANRECO Phase 2 study, confirming 48 patients recruited to evaluate divesiran’s efficacy in PV, with initial topline findings projected for late 2026.
Additionally, leadership transitions have been disclosed. CEO Craig Tooman has departed the company by mutual agreement, with Chairman Iain Ross assuming interim leadership duties. Furthermore, Executive Vice President and Chief Financial Officer Rhonda Hellums has been appointed to the board of directors, effective immediately until the 2026 Annual General Meeting.
Parallel industry developments include TreeFrog Therapeutics’ appointment of Mark Rothera as CEO and Board member, succeeding Frédéric Desdouits, along with co-founders stepping back from daily operations to focus on governance. These changes reflect ongoing strategic realignments within the biotech sector.
Investors interested in detailed analysis can access the comprehensive Pro Research Report on Silence Therapeutics via InvestingPro, which covers over 1,400 U.S. equity securities.
These developments highlight the dynamic progress within the biopharmaceutical landscape, showcasing the pursuit of innovative treatments for hematologic and cardiometabolic conditions with notable financial and strategic positioning.
H.C. Wainwright has upheld its Buy rating on Silence Therapeutics shares, assigning a price target of $75 following discussions with company executives. The firm emphasizes the promising progress of the lead asset divesiran for polycythemia vera, supported by a fully enrolled Phase 2 trial, as well as the broader pipeline advancing toward high-value milestones. Financial health and strategic capital management contribute to a robust outlook for the company’s innovative mRNAi platform.
Key Points
- H.C. Wainwright maintains Buy rating and $75 price target on Silence Therapeutics, indicating substantial upside potential from the current share price.
- The lead drug candidate divesiran, targeting polycythemia vera, has completed full enrollment in its Phase 2 SANRECO trial, with topline data expected in Q3 2026, positioning it as the near-term primary value driver.
- Silence Therapeutics’ pipeline extends beyond its lead asset, with programs like zerlasiran ready for Phase 3 and ongoing developments in hypercholesterolemia, obesity, and delivery technologies, demonstrating the versatility of its mRNAi GOLD platform.
Risks
- Timeline uncertainty regarding topline results for the SANRECO Phase 2 trial, with data not expected until the third quarter of 2026, which may impact near-term valuation.
- Rapid cash burn despite a strong current ratio and cash position could pressure financial sustainability if milestones are delayed or additional capital is needed before 2028.
- Leadership changes, including the CEO’s departure and interim chairman role, may bring transitional challenges affecting operational consistency and investor confidence.